Research Analysts Set Expectations for Geron FY2027 Earnings

Geron Corporation (NASDAQ:GERN) – Research analysts at HC Wainwright cut their FY2027 earnings per share estimates for Geron in a research report issued to clients and investors on Monday, July 13th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn $0.04 per share for the year, down from their prior forecast of $0.05. The consensus estimate for Geron’s current full-year earnings is ($0.02) per share.

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.00.

Geron Stock Performance

Shares of GERN stock opened at $1.42 on Wednesday. The company has a current ratio of 6.78, a quick ratio of 4.96 and a debt-to-equity ratio of 0.52. The firm has a fifty day simple moving average of $1.30 and a two-hundred day simple moving average of $1.45. Geron has a 12 month low of $1.04 and a 12 month high of $2.01. The firm has a market capitalization of $910.96 million, a PE ratio of -12.91 and a beta of 0.60.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.The company had revenue of $51.84 million for the quarter, compared to analysts’ expectations of $50.59 million.

Institutional Trading of Geron

Several institutional investors and hedge funds have recently modified their holdings of GERN. Principal Financial Group Inc. lifted its holdings in shares of Geron by 20.5% in the first quarter. Principal Financial Group Inc. now owns 39,519 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 6,713 shares in the last quarter. Sei Investments Co. grew its holdings in Geron by 23.0% during the first quarter. Sei Investments Co. now owns 41,891 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 7,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Geron by 2.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock worth $627,000 after buying an additional 8,123 shares in the last quarter. E Fund Management Co. Ltd. raised its position in Geron by 12.0% in the 2nd quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 9,849 shares during the last quarter. Finally, LCM Capital Management Inc raised its position in Geron by 80.6% in the 4th quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 10,000 shares during the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.